| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥236.6B | ¥248.4B | -4.7% |
| Operating Income | ¥36.8B | ¥44.6B | -17.6% |
| Ordinary Income | ¥43.1B | ¥51.8B | -16.8% |
| Net Income | ¥22.3B | ¥19.7B | +13.2% |
| ROE | 10.9% | 9.5% | - |
FY2025 consolidated results: Revenue 236.6B yen (YoY -4.7%), Operating Income 36.8B yen (YoY -17.6%), Ordinary Income 43.1B yen (YoY -16.8%), Net Income 22.3B yen (YoY +13.2%). While revenue declined and operating profit decreased substantially, net income achieved double-digit growth driven by non-operating income contributions of 11.1B yen. The company maintains a strong gross profit margin of 50.2%, though SG&A expenses at 82.0B yen (34.7% of revenue) compressed operating margin to 15.5% from prior period levels. Cash and deposits decreased 34.0% YoY to 78.5B yen, reflecting shareholder returns totaling approximately 40B yen (dividends 29.7B yen, share buybacks 10.0B yen) and investment activities. The financial structure remains conservative with equity ratio of 74.3% and minimal interest-bearing debt of 0.1B yen, though free cash flow turned negative at -2.1B yen due to investing activities of 22.2B yen outpacing operating cash flow of 20.1B yen.
Revenue declined 4.7% YoY to 236.6B yen, driven by weak initial sales across segments. The Pharmacy Receipt Computer segment, representing 81.3% of total revenue, declined 6.5% to 192.4B yen primarily due to initial sales decreasing from 10.8B yen to 9.5B yen. Subscription-based revenue showed resilience with recurring billing revenue increasing 2.7% to 71.3B yen and maintenance revenue declining modestly. The Medical Computer segment grew 12.3% to 28.8B yen, with initial sales improving from 1.6B yen to 1.8B yen and billing revenue expanding 23.1%. The Care Welfare IT Systems segment remained flat at 5.7B yen with continued operating losses of 3.8B yen. Other businesses declined slightly to 9.9B yen.
Operating income deteriorated 17.6% to 36.8B yen as cost of sales decreased only 1.0% to 117.8B yen while SG&A expenses remained elevated at 82.0B yen. Personnel costs of 35.3B yen and other operating expenses did not adjust proportionally to revenue decline, resulting in operating margin compression to 15.5% from 18.0% in the prior period. Ordinary income declined at a slower pace of 16.8% to 43.1B yen, supported by non-operating income of 11.1B yen, which included interest and dividend income of 0.5B yen and other financial gains. The gap between operating income (36.8B yen) and ordinary income (43.1B yen) of 6.3B yen represents 2.7% of revenue, indicating material non-operating contributions to profitability.
Extraordinary losses totaled 6.9B yen, comprising impairment losses of 4.1B yen and loss on valuation of securities of 2.7B yen, which suppressed profit before tax to 36.2B yen. After income tax expense of 11.6B yen, net income attributable to owners reached 22.3B yen, achieving 13.2% growth despite operating profit decline. This represents a revenue down, profit up pattern at the net income level, though the underlying operating trend shows revenue down, profit down. The improvement in net income was primarily driven by non-recurring non-operating gains and reduced tax burden relative to prior year's extraordinary items.
The Pharmacy Receipt Computer segment generated revenue of 192.4B yen and operating income of 39.7B yen with a robust operating margin of 20.6%, establishing this as the core business representing 81.3% of consolidated revenue. This segment experienced margin compression as operating income declined 24.5% YoY despite revenue declining only 6.5%, indicating operating deleverage from fixed cost structures. The Medical Computer segment achieved revenue of 28.8B yen with operating income recovering to 0.3B yen (margin 1.1%), showing improvement from prior period's loss position of 4.2B yen. This segment's margin remains substantially below the consolidated average, suggesting early-stage operations or competitive pressures. The Care Welfare IT Systems segment recorded revenue of 5.7B yen with operating loss of 3.8B yen (margin -66.8%), representing a deterioration from prior year's loss of 4.5B yen despite revenue remaining stable. This unprofitable segment continues to drag on consolidated margins and requires strategic review. Segment profitability disparity is material, with the core Pharmacy segment operating at 20.6% margin while Care Welfare remains deeply loss-making, highlighting concentration risk in the dominant segment's performance.
[Profitability] ROE 10.9%, operating margin 15.5% declined from 18.0% YoY reflecting operating deleverage. Gross profit margin remained healthy at 50.2%, though SG&A expense ratio of 34.7% increased from prior period levels. Net profit margin of 9.4% benefited from non-operating income contributions. [Cash Quality] Cash and equivalents 78.5B yen decreased 34.0% YoY, providing short-term debt coverage of 1,570x against minimal interest-bearing debt of 0.1B yen. Operating cash flow to net income ratio of 0.90 indicates moderate cash conversion quality, though below ideal levels. [Investment Efficiency] Asset turnover 0.86 remained stable. Goodwill increased to 20.6B yen from 12.7B yen, representing 7.5% of total assets and requiring monitoring for impairment risk. [Financial Health] Equity ratio 74.3% reflects strong capitalization. Current ratio 224.4% demonstrates ample liquidity coverage. Debt-to-equity ratio 0.35 indicates conservative leverage with virtually no financial risk from interest-bearing obligations.
Operating cash flow of 20.1B yen represents 0.90x of net income, indicating moderate earnings quality with some divergence between reported profits and cash generation. The operating cash flow subtotal before working capital changes stood at 43.8B yen, but was reduced by income taxes paid of 24.1B yen and working capital improvements including receivables decrease of 10.9B yen and inventory reduction of 4.3B yen, offset partially by payables decrease of 1.9B yen. Investing cash flow of -22.2B yen comprised capital expenditures of 9.3B yen and other investments totaling approximately 12.9B yen, suggesting acquisition activities consistent with goodwill increase of 7.9B yen observed on the balance sheet. Financing cash flow of -38.4B yen reflected substantial shareholder returns through share repurchases of 10.0B yen and dividend payments estimated at approximately 28-30B yen. Free cash flow of -2.1B yen indicates insufficient operating cash generation to cover investment activities, with shareholder returns funded through existing cash reserves. Cash and deposits decreased 40.4B yen to 78.5B yen, with the decline primarily attributable to aggressive capital allocation toward shareholder returns totaling approximately 40B yen while maintaining investment activities. The cash position remains adequate for near-term operations though the depletion rate warrants monitoring if operating cash flow does not improve.
Ordinary income of 43.1B yen versus operating income of 36.8B yen shows non-operating net contribution of approximately 6.3B yen, representing 2.7% of revenue. This comprises non-operating income of 11.1B yen partially offset by non-operating expenses of 4.7B yen, with financial income including interest and dividend receipts of 0.5B yen as primary components. The material gap between operating and ordinary income indicates reliance on non-core income sources to support profitability, raising sustainability concerns as these gains may not recur consistently. Extraordinary losses totaled 6.9B yen including impairment losses of 4.1B yen and securities valuation losses of 2.7B yen, representing non-recurring factors that suppressed profit before tax. Excluding these extraordinary items, normalized profit before tax would approximate 43.1B yen, closer to ordinary income levels. Operating cash flow of 20.1B yen falls below net income of 22.3B yen, yielding a cash conversion ratio of 0.90, which suggests some accrual-based earnings that did not convert to cash. The combination of substantial non-operating income contribution, extraordinary losses, and below-unity cash conversion indicates mixed earnings quality requiring closer monitoring of core business cash generation capabilities.
Full-year guidance projects revenue of 227.6B yen (YoY -3.8%), operating income of 33.2B yen (YoY -9.8%), and ordinary income of 39.4B yen (YoY -8.7%). Current period revenue of 236.6B yen represents 104.0% progress against full-year target, indicating actual performance exceeded full-year guidance, suggesting likely upward revision or conservative initial forecasting. Operating income of 36.8B yen achieves 110.8% of full-year target, similarly exceeding expectations. This progress rate substantially above 100% at fiscal year-end confirms the company outperformed its original guidance across all profit metrics. The forecast assumes EPS of 31.69 yen versus actual basic EPS of 35.44 yen, further confirming guidance conservatism. Contract liabilities decreased 1.2B yen, suggesting some deferred revenue recognition acceleration which may impact future period visibility. No order backlog data is available to assess forward revenue pipeline. The guidance framework appears conservative, with actual results demonstrating resilience despite top-line pressure, though management maintains cautious outlook for continued revenue and profit decline in forward periods.
Annual dividend totaled 35.0 yen per share based on consolidated statement data, representing a payout ratio of 1.0% as reported, though calculated payout ratio based on net income indicates approximately 100.7%, suggesting near-total distribution of earnings. Share buyback execution of 10.0B yen during the period demonstrates aggressive capital return policy. Combined with estimated dividends of approximately 24-25B yen (based on 70,515 thousand shares outstanding and 35 yen per share), total shareholder returns approach 34-35B yen. The total return ratio combining dividends and buybacks reaches approximately 153% of net income of 22.3B yen, indicating capital distribution exceeding earnings generation. This aggressive return policy, while shareholder-friendly, raises sustainability concerns given free cash flow of -2.1B yen and operating cash flow of 20.1B yen insufficient to cover total distributions. The company utilized existing cash reserves declining 34.0% to 78.5B yen to fund these returns. Dividend forecast of 14.00 yen for the upcoming period suggests potential dividend reduction from current levels, possibly reflecting management recognition of sustainability constraints.
Segment concentration risk: Pharmacy Receipt Computer segment represents 81.3% of revenue and 108% of consolidated operating income (before adjustments), creating vulnerability to demand fluctuations in pharmacy system market. Any regulatory changes affecting pharmacy operations or competitive pressures in this core market could materially impact consolidated results.
Cash flow and capital allocation sustainability: Free cash flow of -2.1B yen combined with total shareholder returns of approximately 40B yen resulted in cash reserves declining 34.0% to 78.5B yen. Operating cash flow to net income ratio of 0.90 indicates suboptimal cash conversion. Continued high payout ratios exceeding 100% are unsustainable without improved operating cash generation, potentially requiring dividend policy adjustment or curtailment of share buybacks.
Goodwill and intangible asset impairment exposure: Goodwill increased 63.1% to 20.6B yen, representing 7.5% of total assets, while impairment losses of 4.1B yen were recognized in the current period. The Care Welfare IT Systems segment continues operating at -66.8% margin, and Medical Computer segment achieves only 1.1% margin, indicating potential underperformance of acquired assets. Further impairment charges could materially impact future earnings if segment recoveries do not materialize.
[Industry Position] (Reference - Proprietary Analysis)
The company's operating margin of 15.5% and net profit margin of 9.4% reflect specialized software and service provider characteristics, with recurring revenue models supporting higher margins than traditional IT services. ROE of 10.9% demonstrates moderate return on capital despite recent profit pressures. The equity ratio of 74.3% positions the company as highly capitalized relative to typical software industry leverage profiles. Revenue decline of 4.7% YoY contrasts with industry growth trends in healthcare IT, suggesting company-specific challenges in market share or product cycle dynamics. The negative revenue growth combined with margin compression indicates competitive headwinds or market maturation effects. Profitability metrics remain solid in absolute terms, with gross margin of 50.2% characteristic of software businesses, though operating deleverage from fixed cost structures is evident. The conservative financial structure with minimal debt provides financial flexibility, though aggressive capital returns relative to cash generation distinguish this company's capital allocation from peers maintaining higher reinvestment rates. Limited benchmark data precludes detailed peer comparison, though the company's financial health metrics suggest above-average capitalization within Japanese healthcare IT sector.
Operating profit pressure requires attention: Operating income declined 17.6% to 36.8B yen despite revenue declining only 4.7%, indicating operating deleverage from insufficient cost flexibility. The company achieved net income growth of 13.2% only through non-operating income contributions of 6.3B yen (2.7% of revenue), raising sustainability concerns about core business profitability trends. Management focus on improving operating efficiency and aligning cost structures with revenue levels is critical for restoring operating margin toward historical levels above 18%.
Capital allocation policy adjustment likely necessary: Total shareholder returns of approximately 40B yen (combining 10.0B yen buybacks and estimated 24-25B yen dividends) exceeded both net income of 22.3B yen and operating cash flow of 20.1B yen, resulting in free cash flow of -2.1B yen and cash reserves declining 34.0% to 78.5B yen. The calculated payout ratio of 100.7% and total return ratio of approximately 153% indicate unsustainable distribution levels. Forecast dividend of 14.00 yen suggests management recognition of this constraint, representing potential 60% reduction from implied current levels, though still maintaining shareholder-friendly policy within cash generation constraints.
Segment profitability divergence highlights strategic priorities: Pharmacy Receipt Computer segment margin of 20.6% generates substantially all consolidated profits while Care Welfare IT Systems operates at -66.8% margin with persistent losses and Medical Computer achieves only 1.1% margin. Goodwill increased 63.1% to 20.6B yen with impairment losses of 4.1B yen recognized, indicating acquisition integration challenges. Focus on core Pharmacy segment defense while restructuring or divesting underperforming segments would strengthen overall profitability and reduce impairment risk exposure.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.